Integrating extracellular vesicle and circulating cell-free DNA analysis on a single plasma aliquot from breast cancer patients improves the detection of HER2 positivity
Author:
Mugoni Vera, Ciani Yari, Quaini Orsetta, Tomasini Simone, Notarangelo Michela, Vannuccini Federico, Marinelli Alessia, Leonardi Elena, Pontalti Stefano, Martinelli Angela, Rossetto Daniele, Pesce Isabella, Mansy Sheref S., Barbareschi MattiaORCID, Ferro Antonella, Caffo Orazio, Attard Gerhardt, Di Vizio Dolores, D’Agostino Vito Giuseppe, Nardella Caterina, Demichelis Francesca
Abstract
AbstractBackgroundMulti-analyte liquid biopsies represents an emerging opportunity for non-invasive cancer assessment. We developed ONCE (ONe Aliquot for Circulating Elements), a novel multi-analytes liquid biopsy approach for the isolation of extracellular vesicles (EVs) and cell-free DNA (cfDNA) from a single aliquot of blood.MethodsWe assessed ONCE performance to classify HER2-positive early-stage breast cancer (BrCa) patients by combining RNA and DNA signals on n=64 healthy donors (HD) and non–metastatic BrCa patients. Specifically, we investigated EVs-derived RNA (EV-RNA) and cfDNA by next-generation sequencing (NGS) and by digital droplet PCR (ddPCR). Additionally, we utilized imaging flow cytometry to evaluate EVs as potential carriers of the HER2 protein.ResultsWestern blot analysis and immunocapture assay revealed that EVs-enriched proteins were detected at similar levels among the HER2+ and HER2- subtypes. Sequencing of cfDNA and EV-RNA from HER2- and HER2+ patients demonstrated concordance within situmolecular analyses of matched tissues. Combined analysis of the two circulating analytes by ddPCR showed increased sensitivity inERBB2/HER2 detection compared to single nucleic acid components. Multi-analyte liquid biopsy prediction performance was comparable to tissue-based sequencing results from TCGA. Also, we observed HER2 protein on the surface of EVs isolated from the HER2+ BrCa plasma, thus corroborating the potential relevance of studying EVs as companion analyte to cfDNA.ConclusionsThis data confirms the relevance of combining cfDNA and EV-RNA analytes for cancer assessment and supports the ONCE approach as a valuable tool for multi-analytes liquid biopsies’ clinical implementation.
Publisher
Cold Spring Harbor Laboratory
Reference66 articles.
1. The current status of the clinical utility of liquid biopsies in cancer 2. J. Pascual , G. Attard , F.C. Bidard , G. Curigliano , L. De Mattos-Arruda , M. Diehn , A. Italiano , J. Lindberg , J.D. Merker , C. Montagut , N. Normanno , K. Pantel , G. Pentheroudakis , S. Popat , J.S. Reis-Filho , J. Tie , J. Seoane , N. Tarazona , T. Yoshino , N.C. Turner , Ann Oncol, (2022). 3. Plasma cell-free DNA (cfDNA) as a predictive and prognostic marker in patients with metastatic breast cancer 4. J. Phallen , M. Sausen , V. Adleff , A. Leal , C. Hruban , J. White , V. Anagnostou , J. Fiksel , S. Cristiano , E. Papp , S. Speir , T. Reinert , M.W. Orntoft , B.D. Woodward , D. Murphy , S. Parpart-Li , D. Riley , M. Nesselbush , N. Sengamalay , A. Georgiadis , Q.K. Li , M.R. Madsen , F.V. Mortensen , J. Huiskens , C. Punt , N. van Grieken , R. Fijneman , G. Meijer , H. Husain , R.B. Scharpf , L.A. Diaz, Jr. , S. Jones , S. Angiuoli , T. Orntoft , H.J. Nielsen , C.L. Andersen , V.E. Velculescu , Sci Transl Med, 9 (2017). 5. M.C. Cufaro , D. Pieragostino , P. Lanuti , C. Rossi , I. Cicalini , L. Federici , V. De Laurenzi , P. Del Boccio , J Oncol, 2019 (2019) 1639854.
|
|